| abstract |
The present disclosure relates to compositions comprising a transient receptor potential vanilloid-1 (TRPV1) antagonist and an alpha-2 adrenoreceptor agonist useful in the treatment of various forms of pain, including chronic pain (CP) syndromes, inflammatory pain and pain associated with neuropathy and other diseases and disease states; and methods of use thereof. |